Frequently asked questions

PACE Align is the independent intelligence and accountability layer between pharma governance and PSP execution for biologics and long-term specialty injectable therapies. It connects enrolment, treatment-rhythm signals, persistence risk, PSP intervention and programme outcomes so teams can act earlier, verify what happened and protect treatment continuity.

Patients. Adherence. Compliance. Excellence.

No. The PSP continues to deliver patient support. PACE adds the independent intelligence and accountability layer that makes risk, follow-through, continuity and programme performance visible to the appropriate stakeholders.

Biologics and long-term specialty injectable therapies with chronic, recurring treatment pathways across fixed subcutaneous (SC) maintenance, phased initiation-to-maintenance SC and IV-to-SC transitions, including home administration where permitted by the approved product label, local practice and programme design. Therapy coverage is confirmed for each programme.

Programme signals are often fragmented, persistence risk becomes visible late, and activity reports do not always show whether a barrier was resolved. Continuity also suffers when vendors or reporting cycles change. PACE closes that decision gap so teams can see what needs attention, what happened next and whether continuity was protected.

Four role-specific decision views: PAM / Patient Support (programme governance, persistence risk, PSP follow-through and continuity), BU & Brand Performance (patient mix, persistence risk, account/region intelligence and forecast inputs), Medical Affairs (longitudinal treatment patterns, treatment rhythm, barriers, cohorts and evidence gaps) and PSP Operations (priority queue, case ownership, ageing and resolution, and de-identified performance evidence).

De-identified, aggregated enrolment, patient-segment, treatment-pattern, risk, intervention-progress and programme-outcome intelligence. Patient and HCP identities remain protected in pharma views.

The PSP platform helps the operator deliver the programme. PACE gives pharma an independent, consistent intelligence layer across programme signals, PSP execution and outcomes. This supports governance, comparison and continuity even when the operating provider changes.

The PSP executes the programme; PACE makes programme risk, action and outcomes independently visible and governable. It is complementary, not adversarial: PSP teams can use PACE to prioritise work, preserve handover context and demonstrate documented delivery to pharma.

PACE is designed to work alongside existing PSP operations. Workflow, data and integration requirements are agreed for each deployment.

Live or near-current programme intelligence on persistence risk, prioritisation, intervention progress, documented resolution and continuity, using consistent KPI views. Rather than only periodic activity summaries, PACE connects risk, prioritised action, execution progress, documented resolution and continuity.

Independent visibility, persistence-risk early warning, intelligent prioritisation, verified follow-through, consistent KPIs and programme continuity across vendor change.

PACE uses documented treatment-rhythm and programme signals to identify patients at elevated dropout/persistence risk within the implemented model scope. The output supports prioritisation and professional review.

PACE supports digital enrolment and consent where implemented, capturing the programme information needed to begin support. Enrolment and deployment timing depend on the configured workflow.

Timing depends on programme scope, data and workflow readiness, integrations and governance. A confirmed timeline is agreed for each deployment.

PACE is vendor-neutral by design. It is intended to work alongside PSP operators, subject to agreed workflows, permissions, data availability and integration requirements.

Yes, within configured programmes and the agreed data scope. PACE applies consistent programme measures across configured brands and providers, subject to agreed data arrangements and permissions, so programmes can be compared.

PACE supports structured continuity of authorised programme history, open follow-ups, agreed KPI definitions and next steps through approved permissions and data arrangements.

Data responsibilities are defined contractually and in the implemented governance model. PACE applies role-based permissions, and sponsor and PSP responsibilities and data arrangements are agreed for each deployment.

Pharma views are de-identified and aggregated. Authorised PSP care teams may access the patient-level information required for assigned support, under separate permissions.

PACE provides aggregate patient-mix, persistence-risk, treatment-continuity, account/region and programme-performance intelligence that can inform prioritisation and forecast assumptions.

PACE does not infer total-market position from PSP data. It shows account/region programme performance, patient distribution, persistence risk and growth/opportunity trends within the population covered by the programme.

PACE does not automatically translate every action or retained patient into revenue. Use the Value Assessment to explore a scenario under your own programme assumptions; programme impact in a pilot is measured through agreed proof-of-value metrics.

PACE structures programme data to support medical insight, evidence-gap identification and defined RWE analyses. A specific research question, appropriate methods and relevant review are still required.

Not automatically. Structured outputs can support planned analyses; publication or regulatory suitability depends on study design, methods, data quality and relevant review.

PACE helps teams prioritise cases, maintain ownership and handover context, track ageing and resolution, and produce de-identified performance evidence for pharma.